SCHEMBL8201497

SCHEMBL8201497

CC(C)NC(=O)c1cccc(C(=O)NCc2cnn(-c3ccc(S(=O)(=O)N(C)C)cc3)c2)n1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CCR1 P32246 3/20 0.45
ALDH1A1 P00352 7/20 0.43
CA1 P00915 1/20 0.41
CA2 P00918 1/20 0.41
KLKB1 P03952 2/20 0.40
MEN1 O00255 3/20 0.38
KMT2A Q03164 3/20 0.38
NPSR1 Q6W5P4 1/20 0.38
KDM4E B2RXH2 1/20 0.38
ADRB2 P07550 1/20 0.38
MAPK8 P45983 1/20 0.37
MAPK9 P45984 1/20 0.37
MAPK10 P53779 1/20 0.37
NR2F2 P24468 1/20 0.37
LMNA P02545 2/20 0.37
POLB P06746 1/20 0.36
PKM P14618 2/20 0.36
NAMPT P43490 1/20 0.36
KLK1 P06870 1/20 0.36
MAPK1 P28482 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8209278 0.90 MAPK8 (0.46) CCR1CA1CA2ADRB2MAPK8
SCHEMBL8206513 0.89 CA2 (0.54) CA1CA2KMT2AMAPK8MAPK9
SCHEMBL8213929 0.88 CCR1 (0.44) CCR1CA1CA2KLKB1ADRB2
SCHEMBL8205838 0.86 ADRB2 (0.38) CCR1ALDH1A1CA1CA2KLKB1
SCHEMBL8205629 0.86 CNR1 (0.43) ALDH1A1KLKB1MEN1KMT2ANPSR1
SCHEMBL12853254 0.85 HPGD (0.44) ALDH1A1CA1CA2KLKB1MEN1
SCHEMBL8201431 0.85 KLKB1 (0.50) ALDH1A1CA1CA2KLKB1ADRB2
SCHEMBL8210996 0.85 DHODH (0.44) CCR1KLKB1NPSR1KDM4EADRB2
SCHEMBL12853327 0.84 ROCK2 (0.47) ALDH1A1KLKB1KDM4EADRB2LMNA
SCHEMBL8213788 0.83 ADRB2 (0.39) ALDH1A1CA1CA2KLKB1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2132178-B1 JNK INHIBITORS MERCK SHARP & DOHME (US) 2015-08-19 EP disclosed
US-8278337-B2 Substituted pyridines that are JNK inhibitors MERCK SHARP & DOHME (US) 2012-10-02 US disclosed
US-8278337-B2 Substituted pyridines that are JNK inhibitors MERCK SHARP & DOHME (US) 2012-10-02 US disclosed
US-20100179141-A1 NOVEL JNK INHIBITORS SCHERING CORPORATION 2010-07-15 US disclosed
US-20100179141-A1 NOVEL JNK INHIBITORS SCHERING CORPORATION 2010-07-15 US disclosed
WO-2008082487-A2 NOVEL JNK INHIBITORS SCHERING CORPORATION (US) 2008-07-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100179141-A1 NOVEL JNK INHIBITORS MAPK1, MAPKAPK5, MAPK15 CCR1 251/4885ALDH1A1 3650/4885CA1 3679/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.